Most Read, BioBeats Resend & Trivia Answers

Research evidence excerpt

Most Read, BioBeats Resend & Trivia Answers

Biotechnology

EQUITY RESEARCH Industry Report

May 17, 2026

Research Analysts:

Josh Schimmer

310-282-6513 The week finished with an extra FDA purge; while many senior FDA

Josh.Schimmer@cantor.com positions are now unfilled, there is increasing hope that this marks an

Eric Schmidt

212-294-7724 important transition to more stable, pro-science leadership that can keep

Eric.Schmidt@cantor.com the agency far, far away from politics and controversy.

Prakhar Agrawal

212-610-3614 Click HERE for the link to the recording or open this report for the slides.

Prakhar.Agrawal@cantor.com

Olivia Brayer Saunders

212-428-5907 BioBeats Trivia Answer:

Olivia.Brayer@cantor.com

Carter Gould ●The CG in CG Oncology stands for Cold Genesys

212-915-1794

Carter.Gould@cantor.com ●CGON acquired is oncolytic technology from Biosante

Kristen Kluska

212-915-1927 ●Which in turn had acquired it from Cell Genesys

Kristen.Kluska@cantor.com

Imogen Mansfield Most Read Cantor Reports This Week:

929-545-6495

Imogen.Mansfield@cantor.com ●BioBUZZ - What Just Happened? HERE

Steve Seedhouse

212-915-1240 ●BioBUZZ - You're Fired HERE

Steve.Seedhouse@cantor.com

Yanni Souroutzidis ●SEPN: 1Q Update: What Investors Are Missing HERE

929-730-2656

Yanni.Souroutzidis@cantor.com ●TNGX: 1Q26: We Think Patience Will Pay Off HERE

Pete Stavropoulos, Ph.D. ●RIGL: Expands Into Breast Cancer With Veppanu HERE 212-915-1966

Pete.Stavropoulos@cantor.com ●ABCL: Test-ing, Test-ing, Is This Thing On? HERE

Li Watsek

212-915-1221 ●CABA: 1Q26 Update: What Investors Are Missing HERE

Li.Watsek@cantor.com

●IRON: Takeaways from Call With Shadow Jumpers HERE

●BBIO/ALNY/PFE: Modeling CARDIO-TTRansform - Implications For the

Field HERE

Ahead Next Week: